Zanolimumab
- Generic Name
- Zanolimumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 652153-01-0
- Unique Ingredient Identifier
- HG3L8885M0
- Background
Zanolimumab is a fully human monoclonal antibody directed against CD4.
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Phase 2
Terminated
- Conditions
- Metastatic MelanomaMetastatic Renal Cancer
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01160445
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath